Literature DB >> 24585503

Computerized physician order entry-based system to prevent HBV reactivation in patients treated with biologic agents: the PRESCRIB project.

Blanca Sampedro1, Cándido Hernández-López, José Ramón Ferrandiz, Aitziber Illaro, Emilio Fábrega, Antonio Cuadrado, Paula Iruzubieta, Susana Menéndez, Joaquín Cabezas, Javier Crespo.   

Abstract

UNLABELLED: Computerized physician order entry (CPOE) applications are widely used to prevent medical errors. In our center, a CPOE system has been in use since 2009 on both the inpatient and outpatient levels. A new and simple alert was introduced in the CPOE system to notify healthcare providers of the potential risk of viral reactivation when prescribing biological therapies, thereby facilitating the request for a serological profile (hepatitis B surface antigen [HBsAg], anti-HBc, and anti-HBs) in patients who have not had these tests. Between May 2012 and May 2013, a total of 1,076 patients undergoing biological treatment were included in the implementation of the CPOE in our hospital, resulting in the identification of 4 HBsAg-positive and 69 anti-HBc-positive/HBsAg-negative patients, two of them with positive viral loads. Since the implementation of this alert system, over 90% of patients who were prescribed a biological drug (BD) have undergone serological screening to detect hepatitis B virus (HBV) infection. The use of the alert system has increased the screening rate from less than 50% to 94% for HBsAg and from less than 30% to 85% for anti-HBc in patients for whom a BD is prescribed. Six patients received prophylactic antiviral therapy. No patient had HBV reactivation.
CONCLUSION: This study demonstrates the feasibility of implementing a CPOE system that has allowed our hospital to increase the rate of HBV screening. Its use has facilitated the identification of patients at high risk for HBV reactivation and permitted physicians to prescribe prophylactic measures according to current guidelines.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24585503     DOI: 10.1002/hep.27103

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  13 in total

Review 1.  Personalization and Patient Involvement in Decision Support Systems: Current Trends.

Authors:  S Quaglini; L Sacchi; G Lanzola; N Viani
Journal:  Yearb Med Inform       Date:  2015-08-13

2.  Invited Commentary: Screening for hepatitis B in the immigrant population and individuals who are in need of immunosuppressive drug therapy.

Authors:  Robert Perrillo
Journal:  Proc (Bayl Univ Med Cent)       Date:  2015-10

3.  Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.

Authors:  Shigeru Kusumoto; Luca Arcaini; Xiaonan Hong; Jie Jin; Won Seog Kim; Yok Lam Kwong; Marion G Peters; Yasuhito Tanaka; Andrew D Zelenetz; Hiroshi Kuriki; Günter Fingerle-Rowson; Tina Nielsen; Eisuke Ueda; Hanna Piper-Lepoutre; Gila Sellam; Kensei Tobinai
Journal:  Blood       Date:  2018-10-19       Impact factor: 22.113

Review 4.  Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations.

Authors:  Fernando Bessone; Melisa Dirchwolf
Journal:  World J Hepatol       Date:  2016-03-18

5.  Rheumatologists' awareness of hepatitis B reactivation before immunosuppressive therapy.

Authors:  Bilal Toka; Ahmet Tarik Eminler; Emel Gönüllü; Mukaddes Tozlu; Mustafa Ihsan Uslan; Erkan Parlak; Oğuz Karabay; Aydin Seref Koksal
Journal:  Rheumatol Int       Date:  2019-09-13       Impact factor: 2.631

6.  Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration.

Authors:  Christine M Hunt; Lauren A Beste; Elliott Lowy; Ayako Suzuki; Cynthia A Moylan; Hans L Tillmann; George N Ioannou; Joseph K Lim; Michael J Kelley; Dawn Provenzale
Journal:  World J Gastroenterol       Date:  2016-05-21       Impact factor: 5.742

7.  Hepatitis B Screening Before Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug Therapy: Many Roads to Improvement.

Authors:  Alfredo Aguirre; Jinoos Yazdany
Journal:  J Rheumatol       Date:  2021-11-01       Impact factor: 5.346

Review 8.  Hepatitis B Reactivation with Novel Agents in Non-Hodgkin's Lymphoma and Prevention Strategies.

Authors:  Oluwatobi O Ozoya; Lubomir Sokol; Samir Dalia
Journal:  J Clin Transl Hepatol       Date:  2016-06-15

9.  Outcomes of the implementation of the computer-assisted HBView system for the prevention of hepatitis B virus reactivation in chemotherapy patients: a retrospective analysis.

Authors:  Akimasa Sanagawa; Junko Kuroda; Arufumi Shiota; Noriko Kito; Masashi Takemoto; Yoshihiro Kawade; Tetsuo Esaki; Kazunori Kimura
Journal:  J Pharm Health Care Sci       Date:  2015-11-04

10.  Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study.

Authors:  María Buti; María L Manzano; Rosa M Morillas; Montserrat García-Retortillo; Leticia Martín; Martín Prieto; María L Gutiérrez; Emilio Suárez; Mariano Gómez Rubio; Javier López; Pilar Castillo; Manuel Rodríguez; José M Zozaya; Miguel A Simón; Luis E Morano; José L Calleja; María Yébenes; Rafael Esteban
Journal:  PLoS One       Date:  2017-09-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.